ABT · XBRL financial data

Abbott Laboratories financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ABT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	34,608	43,075	43,653	40,109	41,950	44,328
Cost of goods and services sold	15,003	18,537	19,142	17,975	18,706	19,319
Research and development	2,420	2,742	2,888	2,741	2,844	2,942
Selling, general and administrative	9,696	11,324	11,248	10,949	11,697	12,332
Operating income (loss)	5,357	8,425	8,362	6,478	6,825	8,053
Interest income	46	43	183	385	344	308
Interest expense	546	533	558	637	559	493
Other income (expense)	103	277	321	479	376	548
Income tax expense (benefit)	497	1,140	1,373	941	(6,389)	1,942
Net income (loss)	4,495	7,071	6,933	5,723	13,402	6,524
Earnings per share, basic USD per share	2.52	3.97	3.94	3.28	7.67	3.73
Earnings per share, diluted USD per share	2.50	3.94	3.91	3.26	7.64	3.72
Weighted average shares, basic millions of shares	1,773	1,775	1,753	1,740	1,740	1,741
Weighted average shares, diluted millions of shares	1,786	1,789	1,764	1,749	1,748	1,748

Fiscal years (ABT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	6,838	9,799	9,882	6,896	7,616	8,522
Short-term investments	310	450	288	383	351	417
Accounts receivable	6,414	6,487	6,218	6,565	6,925	7,929
Inventory	5,012	5,157	6,173	6,570	6,194	6,488
Total current assets	20,441	24,239	25,224	22,670	23,656	25,996
Property and equipment, net	9,029	8,959	9,162	10,154	10,658	11,816
Right-of-use asset	1,101	1,153	1,116	1,122	1,075	1,126
Goodwill	23,744	23,231	22,799	23,679	23,108	24,035
Total assets	72,548	75,196	74,438	73,214	81,414	86,713
Current portion of long-term debt	7	754	2,251	1,080	1,500	3,033
Total current liabilities	11,907	13,105	15,489	13,841	14,157	16,496
Long-term debt	18,527	17,296	14,522	13,599	12,625	9,896
Lease liability, non-current	902	956	943	949	896	931
Retained earnings	27,627	31,528	35,257	37,554	47,261	49,781
Total stockholders' equity	32,784	35,802	36,686	38,603	47,664	52,130
Total liabilities and equity	72,548	75,196	74,438	73,214	81,414	86,713
Common shares outstanding (cover page) millions of shares	1,772	1,763	1,738	1,735	1,734	1,738

Fiscal years (ABT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	4,495	7,071	6,933	5,723	13,402	6,524
Stock-based compensation	546	640	685	644	673	664
Net cash from operating activities	7,901	10,533	9,581	7,261	8,558	9,566
Purchases of property and equipment	2,177	1,885	1,777	2,202	2,207	2,171
Net cash from investing activities	(2,215)	(2,008)	(1,740)	(3,133)	(2,338)	(2,422)
Share repurchases	403	2,299	3,795	1,227	1,295	893
Dividends paid	2,560	3,202	3,309	3,556	3,836	4,116
Proceeds from long-term debt	1,281	4	—	—	—	—
Repayments of long-term debt	1,333	48	—	—	—	—
Net cash from financing activities	(2,779)	(5,494)	(7,636)	(7,091)	(5,404)	(6,309)
Net change in cash	2,978	2,961	83	(2,986)	720	906

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Abbott Laboratories	4,052	13,013	1,737*	1.7B	Q3 FY26 10-QSep 30, 2026
Merck	9,550	18,085	6,558*	2.5B	Q3 FY26 10-QSep 30, 2026
AbbVie	10,774	17,404	7,606*	1.8B	Q3 FY26 10-QSep 30, 2026
Amgen	13,190	10,365	4,241*	540.9M	Q3 FY26 10-QSep 30, 2026
Johnson & Johnson	16,910	25,399	7,720*	2.4B	Q3 FY26 10-QSep 27, 2026
Pfizer	1,824	16,583	5,375*	5.7B	Q3 FY26 10-QSep 27, 2026
Vertex Pharmaceuticals	4,979	3,441	643*	253.5M	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.